Catalog No.: PC-38644Not For Human Use, Lab Use Only.
RGX-104 (Abequolixron) is a small-molecule liver X receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the apolipoprotein E (ApoE) gene, enhances anti-tumor immune responses and inhibits proliferation of tumor cells.
RGX-104 (Abequolixron) is a small-molecule liver X receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the apolipoprotein E (ApoE) gene, enhances anti-tumor immune responses and inhibits proliferation of tumor cells.
RGX-104 (Abequolixron) activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment.
RGX-104 (Abequolixron) selectively targets and binds to LXRbeta (NR1H2), thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes.
